The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Thrombosis Research

• Publication date

  2009-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.thromres.2008.11.005PMID 19135705
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.

  2009cited by this paper
• Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents

  2009cited by this paper
• Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.

  2008cited by this paper
• Reproducibility and standardized reporting of the vasodilator-stimulated phosphoprotein phosphorylation assay

  2008cited by this paper
• Calcium channel blockers reduce the antiplatelet effect of clopidogrel

  2008cited by this paper
• Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests

  2008cited by this paper
• P2 receptors, platelet function and pharmacological implications

  2008cited by this paper
• Aspirin responsiveness in healthy volunteers measured with multiple assay platforms.

  2008cited by this paper
• Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events

  2007cited by this paper
• Thienopyridines in cardiovascular disease: Focus on Clopidogrel resistance

  2007cited by this paper
• Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100

  2007cited by this paper
• Determination of aspirin responsiveness by use of whole blood platelet aggregometry.

  2007cited by this paper
• Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.

  2007cited by this paper
• Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate analyzer--comparison with two flow cytometric methods.

  2007cited by this paper
• Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

  2007cited by this paper
• Measuring antiplatelet drug effects in the laboratory.

  2007cited by this paper
• Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention.

  2007cited by this paper
• Impaired platelet responsiveness to clopidogrel identified by flow cytometric vasodilator-stimulated phosphoprotein (VASP) phosphorylation in patients with subacute stent thrombosis

  2007cited by this paper
• The "clopidogrel resistance" trap.

  2007cited by this paper
• Clopidogrel resistance — The cardiologist's perspective

  2007cited by this paper
• Control of Aspirin Effect in Chronic Cardiovascular Patients Using two Whole Blood Platelet Function Assays: PFA-100 and Multiple Electrode Aggregometry

  2007cited by this paper
• Vollblutaggregometrie zur Kontrolle der Wirksamkeit von Azetylsalizylsäure bei Patienten mit koronarer Herzkrankheit

  2007cited by this paper
• [Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate].

  2007cited by this paper
• High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

  2006cited by this paper
• Platelet function in patients with acute coronary syndrome (ACS) predicts recurrent ACS

  2006influential reference
• Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood

  2006cited by this paper
• Determination of clopidogrel resistance by whole blood platelet aggregometry and inhibitors of the P2Y12 receptor.

  2006cited by this paper
• Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

  2005cited by this paper
• Heparin Therapy Leads to Platelet Activation and Prolongation of PFA-100 Closure Time

  2005cited by this paper
• Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases

  2005cited by this paper
• Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.

  2004cited by this paper
• Prospective Evaluation of von Willebrand Factor Release After Multiple and Single Stenting

  2004cited by this paper
• Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction

  2004cited by this paper
• High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

  2004cited by this paper
• Failure of clopidogrel to reduce platelet reactivity and activation following standard dosing in elective stenting: implications for thrombotic events and restenosis

  2004cited by this paper
• Time lag in platelet function inhibition by clopidogrel in stroke patients as measured by PFA‐100

  2004cited by this paper
• Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets

  2003cited by this paper
• Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement

  2003cited by this paper
• Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin.

  2003cited by this paper
• Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.

  2002cited by this paper
• Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction.

  2001cited by this paper
• Impaired Platelet Function among Platelet Donors

  2001cited by this paper
• Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery.

  2000cited by this paper
• Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel.

  1999cited by this paper
• Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease

  1999cited by this paper
• Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty.

  1997cited by this paper
• Free radicals, antioxidants, and endothelial cell damage after percutaneous transluminal coronary angioplasty

  1993cited by this paper
• Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection.

  1992cited by this paper
• Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo.

  1991cited by this paper

• Enhanced platelet inhibition by clopidogrel and risk of bleeding in patients requiring oral anticoagulation after drug-eluting stent implantation.

  2019cites this paper
• Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis

  2019cites this paper
• Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention

  2018cites this paper
• Does percutaneous coronary stent implantation increase platelet reactivity?

  2017cites this paper
• Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?

  2016cites this paper
• How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?

  2015cites this paper
• Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease?

  2015cites this paper
• Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia.

  2015cites this paper
• A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity

  2014cites this paper
• Impact of high post-loading platelet aggregation on 30-day clinical outcomes after primary percutaneous coronary intervention. The antiplatelet regimen tailoring after primary PCI (ART-PCI) trial.

  2013cites this paper
• Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study.

  2013cites this paper
• Clinical Implications of Platelet—Vessel Interaction

  2013cites this paper
• Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.

  2013cites this paper
• Enhanced antiplatelet effect of enteric- -coated acetylsalicylic acid in co-administration with pantoprazole

  2013influential citation
• Dual non-responsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin.

  2013cites this paper
• Plättchenfunktionstestung: Erwartung und Realität

  2013cites this paper
• Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy.

  2013cites this paper
• Role of platelet reactivity in patients undergoing percutaneous coronary intervention

  2012cites this paper
• Analysis of Aptamer Concentrations in Cynomolgus Macaque Plasma and in the Serum Stability Study

  2012cites this paper
• Prevalence of poor biological response to clopidogrel

  2012cites this paper
• Continuous thrombin infusion leads to a bleeding phenotype in sheep.

  2012cites this paper
• ARC15105 Is a Potent Antagonist of Von Willebrand Factor Mediated Platelet Activation and Adhesion

  2012cites this paper
• Effect of chronic kidney disease on platelet reactivity to dual-antiplatelet therapy in patients treated with drug-eluting stents

  2012cites this paper
• Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests.

  2012cites this paper
• Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS‐PCI study

  2012cites this paper
• Stent implantation in the superficial femoral artery: short thrombelastometry-derived coagulation times identify patients with late in-stent restenosis.

  2012cites this paper
• Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention

  2012cites this paper
• Pharmacodynamic Effect of Switching Therapy in Patients With High On-Treatment Platelet Reactivity and Genotype Variation With High Clopidogrel Dose Versus Prasugrel: The RESET GENE Trial

  2012cites this paper
• Role of platelet function testing in clinical practice: current concepts and future perspectives.

  2011cites this paper
• Diurnal variation in platelet inhibition by clopidogrel

  2011cites this paper
• Clinical, genetic and confounding factors determine the dynamics of the in vitro response/non response to clopidogrel

  2011cites this paper
• Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis

  2010cites this paper
• Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases

  2010cites this paper
• Ticagrelor: from discovery to Phase III clinical trial.

  2010cites this paper
• The Influence of Proton Pump Inhibitors on the Antiplatelet Potency of Clopidogrel Evaluated by 5 Different Platelet Function Tests

  2010cites this paper
• Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator‐stimulated phosphoprotein phosphorylation assay

  2010cites this paper
• Cross validation of aspirin effect in healthy individuals by Impact-R and PFA-100: A double blind randomized placebo controlled trial

  2009cites this paper
• Evaluation of laboratory methods for testing anti-platelet drug resistance

  2009cites this paper
• [Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].

  2009cites this paper
• Current World Literature

  2002cites this paper